Rank;Global Rank;Institution;Country;Sector
1;33;SINTEF Group;NOR;Companies
2;581;France Telecom, S.A.;FRA;Companies
3;930;BMW AG;DEU;Companies
4;955;GlaxoSmithKline, United Kingdom;GBR;Companies
5;1418;Robert Bosch GmbH;DEU;Companies
6;1460;Renault, S.A.S.;FRA;Companies
7;1847;Electricite de France, S.A.;FRA;Companies
8;2015;Bayer AG, Germany;DEU;Companies
9;2216;Daimler AG;DEU;Companies
9;2216;Sincrotrone Trieste;ITA;Companies
11;2492;Merck KGaA, Germany;DEU;Companies
12;2627;IMEC International;BEL;Companies
13;3136;BMJ Group;GBR;Companies
13;3136;Hoffmann-La Roche, GmbH., Germany;DEU;Companies
15;3522;AstraZeneca, Sweden;SWE;Companies
15;3522;Atomic Weapons Establishment;GBR;Companies
15;3522;Bruker Corp;DEU;Companies
15;3522;Hoffmann-La Roche, Ltd., Switzerland;CHE;Companies
15;3522;Novartis Farma, S.p.A., Italy;ITA;Companies
15;3522;Novartis Institutes for Biomedical Research, Switzerland;CHE;Companies
15;3522;Novartis, Switzerland;CHE;Companies
22;4256;ARUP;GBR;Companies
22;4256;AstraZeneca, United Kingdom;GBR;Companies
22;4256;Carl Zeiss AG;DEU;Companies
22;4256;Eli Lilly and Company Ltd., United Kingdom;GBR;Companies
22;4256;European XFEL GmbH;DEU;Companies
22;4256;Fusion for Energy;ESP;Companies
22;4256;GlaxoSmithKline, Belgium;BEL;Companies
22;4256;Intesa Sanpaolo S.p.A.;ITA;Companies
22;4256;Novo Nordisk A/S;DNK;Companies
22;4256;Pfizer Inc., United Kingdom;GBR;Companies
22;4256;Sanofi-Aventis, Germany;DEU;Companies
22;4256;Telecom Italia S.p.A.;ITA;Companies